Indonesian Journal of Pharmaceutical Science and Technology
Pharmacogenomics β-Blockers in Cardiovascular Disease: Implications for Blood Pressure and Clinical Outcomes
Abstrak
Hypertension is a chronic condition that increases the risk of cardiovascular disease and death. β-blockers, including atenolol, metoprolol, bisoprolol, and carvedilol, lower blood pressure by blocking adrenergic receptors. However, variations in response and side effects are often influenced by genetic differences that affect drug metabolism and action. This narrative review analyzes studies published between 2014 and 2024 in PubMed, ScienceDirect, and Google Scholar using keywords related to genetic variation, β-blockers, hypertension, pharmacogenetics, and polymorphisms. Original studies in English, clinical trials on genetic polymorphisms and β-blocker response were included; reviews and incomplete studies were excluded. Clinical outcomes included changes in systolic and diastolic blood pressure, heart rate, hypotension, aortic root z-score, LVOT gradient, NT-proBNP, and premature ventricular contractions, which were associated with polymorphisms in the ADRB1, ADRB2, ACY3, FGD5, SLC4A1, and SLC25A31 genes. Metabolic outcomes, impaired fasting glucose, new-onset diabetes, and melatonin metabolite changes were associated with variants in PRKCB, DPYS, PAH, and PLEKHH2. Most data came from European and North American populations, with limited representation from Asia, limiting generalizability. These findings support the use of pharmacogenomics to personalize β-blocker therapy and improve hypertension management, despite challenges related to high costs, limited infrastructure, the lack of clinical guidelines, and population heterogeneity.
Kata Kunci
Teks Lengkap:
PDF (English)Referensi
Liatakis I, Manta E, Tsioufis C. Hypertension and Atrial Fibrillation: Epidemiological Data, Pathogenesis, and Therapeutic Implications. American Journal of Hypertension. 2019;32(8):725–6. doi:10.1093/ajh/hpz077
Putri LR, Fibriana AI, Azam M. Prevalence and Risk Factors of Hypertension Among Young Adults (26-35 Years Old) in Indonesia: Analysis of Secondary Data from Riskesdas 2018. Epidemiology; 2024. Available from: http://medrxiv.org/lookup/doi/10.1101/2024.06.10.24308678 doi:10.1101/2024.06.10.24308678
World Health Organization. Monitoring health for the SDGs, Sustainable Development Goals. 2024. Available from: https://www.who.int/publications/i/item/9789240094703.
Husma SH, Setiarini A, Sartika RAD, Putri PN. Hubungan Jenis Kelamin, Usia dan Frekuensi Konsumsi Mie Instan pada Pasien Hipertensi di Wilayah Kerja Puskesmas Kemiri Muka, Kota Depok. Mal Nurse J. 2025;7(3):1392–408. doi:10.33024/mnj.v7i3.18811
Kasaudhan SM, Ghimire A, Sharma SK, Baral D, Jha N, Singh SB. Undiagnosed and Uncontrolled Hypertension and Access to Health Care among Residents of an Urban Area of Eastern Nepal: a Cross-sectional Study. Kathmandu Univ Med J. 2022;20(3):273–9. doi:10.3126/kumj.v20i3.53928
Gebremichael GB, Berhe KK, Zemichael TM. Uncontrolled hypertension and associated factors among adult hypertensive patients in Ayder comprehensive specialized hospital, Tigray, Ethiopia, 2018. BMC Cardiovasc Disord. 2019;19(1):121. doi:10.1186/s12872-019-1091-6
Farhadi F, Aliyari R, Ebrahimi H, Hashemi H, Emamian MH, Fotouhi A. Prevalence of uncontrolled hypertension and its associated factors in 50–74 years old Iranian adults: a population-based study. BMC Cardiovasc Disord. 2023;23(1):318. doi:10.1186/s12872-023-03357-x
Alhawari H, Jarrar Y, Zihlif M, Wahbeh A, Alshelleh S, Ojjoh K, et al. Variability in Response to Valsartan and Its Relationship With AGT M235T Genotype and Other Nongenetic Parameters Among a Sample of Hypertensive Individuals in Jordan: A Prospective Pilot Study. Health Science Reports. 2025;8(4):e70611. doi:10.1002/hsr2.70611
Derington CG, Berchie RO, Mohanty AF, Jacobs JA, Xu Y, King JB, et al. First-Line β-Blocker Use for Hypertension in the Veterans Health Administration. JAMA Netw Open. 2025;8(8):e2529026. doi:10.1001/jamanetworkopen.2025.29026
Magvanjav O, McDonough CW, Gong Y, McClure LA, Talbert RL, Horenstein RB, et al. Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke. 2017;48(5):1337–43. doi:10.1161/STROKEAHA.116.015936
Farzam K, Jan A. Beta Blockers. In. Treasure Island: StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532906/.
Park JJ, Park H, Cho H, Lee H, Kim KH, Yoo B, et al. β‐Blockers and 1‐Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate. JAHA. 2019;8(4):e011121. doi:10.1161/JAHA.118.011121
Robiou-du-Pont S, Anand SS, Morrison KM, McDonald SD, Atkinson SA, Teo KK, et al. Parental and offspring contribution of genetic markers of adult blood pressure in early life: The FAMILY study. Dubé MP, editor. PLoS ONE. 2017;12(10):e0186218. doi:10.1371/journal.pone.0186218
Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet. 2017;49(3):403–15. doi:10.1038/ng.3768
the Million Veteran Program, Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50(10):1412–25. doi:10.1038/s41588-018-0205-x
Pinheiro DS, Santos RS, Jardim PCBV, Silva EG, Reis AAS, Pedrino GR, et al. The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients. Ciccacci C, editor. PLOS ONE. 2019;14(8):e0221248.
Gong Y, Wang Z, Beitelshees AL, McDonough CW, Langaee TY, Hall K, et al. Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans. Hypertension. 2016;67(3):556–63.
Razaq A, Khan A, Shah ST, Ullah S. Association of insertion /deletion polymorphism of ace gene with essential hypertension in patients of Khyber Pakhtunkhwa. Pakistan Journal of Medical Sciences. 2023;40(3).
Devyatkin VA, Redina OE, Muraleva NA, Kolosova NG. Single-Nucleotide Polymorphisms (SNPs) Both Associated with Hypertension and Contributing to Accelerated-Senescence Traits in OXYS Rats. International Journal of Molecular Sciences. 2020;21(10):3542.
Dawed AY, Mari A, Brown A, McDonald TJ, Li L, Wang S, et al. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. The Lancet Diabetes & Endocrinology. 2023;11(1):33–41. doi:10.1016/S2213-8587(22)00340-0
Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research. 2019;111:59–67. doi:10.1016/j.jpsychires.2019.01.003
Lou JS, Su M, Wang J, Do HN, Miao Y, Huang XY. Distinct binding conformations of epinephrine with α- and β-adrenergic receptors. Exp Mol Med. 2024;56(9):1952–66. doi:10.1038/s12276-024-01296-x
Do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three Generations of β-blockers: History, Class Differences and Clinical Applicability. Current Hypertension Reviews. 2019;15(1):22–31.
Park K, Park TH. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older patients with heart failure and preserved ejection fraction. International Journal of Cardiology Cardiovascular Risk and Prevention. 2023;18:200201. doi:10.1016/j.ijcrp.2023.200201
Chan You S, Krumholz HM, Suchard MA, Schuemie MJ, Hripcsak G, Chen R, et al. Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study. Hypertension. 2021;77(5):1528–38. doi:10.1161/HYPERTENSIONAHA.120.16402
Gao X, Liu M, Xu J, Li L, Chen M, Lang X, et al. Impact of in-hospital oral beta-blockers initiation on long-term outcomes in ST-elevation myocardial infarction patients with cardiogenic shock. Front Med. 2025;12:1666977. doi:10.3389/fmed.2025.1666977
Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, et al. Genome‐Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β‐Blockers. JAHA. 2018;7(5):e006463. doi:10.1161/JAHA.117.006463
Yang HQ, Wang LP, Gong YY, Fan XX, Zhu SY, Wang XT, et al. β2 -Adrenergic Stimulation Compartmentalizes β1 Signaling Into Nanoscale Local Domains by Targeting the C-Terminus of β1 -Adrenoceptors. Circulation Research. 2019;124(9):1350–9. doi:10.1161/CIRCRESAHA.118.314322
Shannon TR, Bare DJ, Van Dijk S, Raofi S, Huynh TNM, Xiang YK, et al. Subcellular Propagation of Cardiomyocyte β-Adrenergic Activation of Calcium Uptake Involves Internal β-Receptors and AKAP7. Function. 2022;3(3):zqac020. doi:10.1093/function/zqac020
Diaconu C, Marcu D, Bratu O, Stanescu AM, Gheorghe G, Hlescu A, et al. Beta-blockers in Cardiovascular Therapy: A Review. JMMS. 2019;6(2):216–23. doi:10.22543/7674.62.P216223
Xu W, Li J, Ju J, Liu M, Wang W, Cheng M, et al. The beta1-adrenergic receptor in the heart. Cell Death Discov. 2025;12(1):46. doi:10.1038/s41420-025-02907-w
Humphries S, Mars K, Hofmann R, Held C, Olsson EMG. Randomized evaluation of routine beta-blocker therapy after myocardial infarction quality of life (RQoL): design and rationale of a multicentre, prospective, randomized, open, blinded endpoint study. Banach M, editor. European Heart Journal Open. 2023;3(3):oead036. doi:10.1093/ehjopen/oead036
Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. Cardiovasc Diabetol. 2019;18(1):163. doi:10.1186/s12933-019-0967-1
Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, et al. Use of Genetic Variants Related to Antihypertensive Drugs to Inform on Efficacy and Side Effects. Circulation. 2019;140(4):270–9.
Castaño-Amores C, Antúnez-Rodríguez A, Pozo-Agundo A, García-Rodríguez S, Martínez-González LJ, Dávila-Fajardo CL. Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome. Biomedicine & Pharmacotherapy. 2023;169:115869.
Rimpelä JM, Kontula KK, Fyhrquist F, Donner KM, Tuiskula AM, Sarin AP, et al. Replicated Evidence for Aminoacylase 3 and Nephrin Gene Variations to Predict Antihypertensive Drug Responses. Pharmacogenomics. 2017;18(5):445–58.
Chang S, Gong Y, McDonough C, Langaee T, Nasiri Kenari N, Beitelshees A, et al. Melatonin Pathway and Atenolol‐Related Glucose Dysregulation: Is There a Correlation? Clinical and Translational Science. 2016;9(2):114–22.
Van Driest SL, Sleeper LA, Gelb BD, Morris SA, Dietz HC, Forbus GA, et al. Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. The Journal of Pediatrics. 2020;222:213–20.
Shahin MH, Rouby NE, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, et al. β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies. J Clin Pharmacol. 2019;59(11):1462–70.
Singh S, El Rouby N, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, et al. Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta‐Blockers in European Americans. Clinical and Translational Science. 2019;12(5):497–504.
Peller M, Ozierański K, Balsam P, Grabowski M, Filipiak KJ, Opolski G. Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials. Cardiology Journal. 2015;22(6):708–16. Available from: https://journals.viamedica.pl/cardiology_journal/article/view/41777
Chang SW, McDonough CW, Gong Y, Johnson TA, Tsunoda T, Gamazon ER, et al. Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes. The Pharmacogenomics Journal. 2018;18(1):106–12.
De Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, et al. Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics. 2016;12(8):129. Available from: http://link.springer.com/10.1007/s11306-016-1076-8
Cooper-DeHoff RM, Hou W, Weng L, Baillie RA, Beitelshees AL, Gong Y, et al. Is a Diabetes Mellitus–Linked Amino Acid Signature Associated With β-Blocker–Induced Impaired Fasting Glucose? Circulation: Cardiovascular Genetics. 2014;7(2):199–205.
Raimoglou D. Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy. Anatol J Cardiol. 2024;150–7. doi:10.14744/AnatolJCardiol.2023.3898
Wu D, Li G, Deng M, Song W, Huang X, Guo X, et al. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension. J Int Med Res. 2015;43(3):424–34. doi:10.1177/0300060514563151
Dalangin R, Kim A, Campbell RE. The Role of Amino Acids in Neurotransmission and Fluorescent Tools for Their Detection. International Journal of Molecular Sciences. 2020;21(17):6197.
Hiltunen TP, Donner KM, Sarin AP, Saarela J, Ripatti S, Chapman AB, et al. Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. JAHA. 2015;4(1):e001778. doi:10.1161/JAHA.115.001778
Si D, Wang J, Xu Y, Chen X, Zhang M, Zhou H. Association of Common Polymorphisms in β1-adrenergic Receptor With Antihypertensive Response to Carvedilol: Journal of Cardiovascular Pharmacology. 2014;64(4):306–9.
Muslimova E, Rebrova T, Kondratieva D, Korepanov V, Sonduev E, Kozlov B, et al. Expression of the β1-adrenergic receptor (ADRB1) gene in the myocardium and β-adrenergic reactivity of the body in patients with a history of myocardium infraction. Gene. 2022;844:146820.
Myagmar BE, Flynn JM, Cowley PM, Swigart PM, Montgomery MD, Thai K, et al. Adrenergic Receptors in Individual Ventricular Myocytes: The Beta-1 and Alpha-1B Are in All Cells, the Alpha-1A Is in a Subpopulation, and the Beta-2 and Beta-3 Are Mostly Absent. Circulation Research. 2017;120(7):1103–15.
McCrink KA, Brill A, Jafferjee M, Valero TR, Marrero C, Rodriguez MM, et al. β1 -Adrenoceptor Arg389Gly Polymorphism Confers Differential β-Arrestin-Binding Tropism in Cardiac Myocytes. Pharmacogenomics. 2016;17(15):1611–20. doi:10.2217/pgs-2016-0094
Moric-Janiszewska E, Smolik S, Szydłowski L, Kapral M. Associations between Selected ADRB1 and CYP2D6 Gene Polymorphisms in Children with Ventricular and Supraventricular Arrhythmias. Medicina. 2023;59(12):2057.
Atici A, Rasih-Sonsoz M, Ali-Barman H, Durmaz E, Demirkiran A, Gulsen K, et al. The Role of Beta-1 Receptor Gene Polymorphism in Beta-Blocker Therapy for Vasovagal Syncope. RIC. 2020;72(5):3938. doi:10.24875/RIC.20003319
Pranckevicius NA, Scott AL, Rourke AJ, Saleem R, Wearing OH, Scott GR. Catecholamine synthesis and secretion by adrenal chromaffin cells are reduced in deer mice native to high altitude. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2025;328(3):R274–86. doi:10.1152/ajpregu.00194.2024
Liu Y, Wang Y, Zhou M, Zhang L, Pang Y, Wang C, et al. Metabolism and secretion mechanism of catecholamine syndrome and related treatment strategies. J Xiangya Med. 2020;5:39–39. doi:10.21037/jxym-20-88
Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, et al. Metabolite Profiling and Cardiovascular Event Risk: A Prospective Study of 3 Population-Based Cohorts. Circulation. 2015;131(9):774–85.
Chen H, Luo H, Zhou J, Yu M, Qing T, Wang Y, et al. Polymorphisms in genes related to inflammation and endothelial function are associated with ischemic stroke and other vascular events in populations at high risk of stroke. J Cent Nerv Syst Dis. 2025;17:11795735241312660. doi:10.1177/11795735241312660
Farhan MA, Azad AK, Touret N, Murray AG. FGD5 Regulates VEGF Receptor-2 Coupling to PI3 Kinase and Receptor Recycling. Arteriosclerosis, Thrombosis, and Vascular Biology. 2017;37(12):2301–10.
Ta N, Liu M, Wang Y, Zeng F, Nie F, Shang M, et al. Association of polymorphisms in endothelial dysfunction-related genes with susceptibility to essential hypertension in elderly Han population in Liaoning province, China. Rev Cardiovasc Med. 2021;22(3):895. doi:10.31083/j.rcm2203096
Li B, Zhang Q, Zhang H, Wang C, Xiu R. Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension. Bioscience Reports. 2020;40(5):BSR20200436. doi:10.1042/BSR20200436
Majidinia M, Rasmi Y, Khadem Ansari MH, Seyed-Mohammadzad M, Saboory E, Shirpoor A. Metoprolol Improves Endothelial Function in Patients with Cardiac Syndrome X. Iran J Pharm Res. 2016;15(3):561–6. PubMed PMID: 27980592; PubMed Central PMCID: PMC5149044.
Bertocchio JP, Genetet S, Da Costa L, Walsh SB, Knebelmann B, Galimand J, et al. Red Blood Cell AE1/Band 3 Transports in Dominant Distal Renal Tubular Acidosis Patients. Kidney International Reports. 2020;5(3):348–57. doi:10.1016/j.ekir.2019.12.020
Zhou Y, Qiu L, Xiao Q, Wang Y, Meng X, Xu R, et al. Obesity and diabetes related plasma amino acid alterations. Clinical Biochemistry. 2013;46(15):1447–52.
Love KM, Jahn LA, Hartline LM, Patrie JT, Barrett EJ, Liu Z. Insulin-mediated muscle microvascular perfusion and its phenotypic predictors in humans. Sci Rep. 2021;11(1):11433. doi:10.1038/s41598-021-90935-8
Xia AY, Zhu H, Zhao ZJ, Liu HY, Wang PH, Ji LD, et al. Molecular Mechanisms of the Melatonin Receptor Pathway Linking Circadian Rhythm to Type 2 Diabetes Mellitus. Nutrients. 2023;15(6):1406.
Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Research. 2014;42(1):199–205.
Wang J, Casimiro-Garcia A, Johnson BG, Duffen J, Cain M, Savary L, et al. A protein kinase C α and β inhibitor blunts hyperphagia to halt renal function decline and reduces adiposity in a rat model of obesity-driven type 2 diabetes. Sci Rep. 2023;13(1):16919. doi:10.1038/s41598-023-43759-7
Luo JQ, Ren H, Chen MY, Zhao Q, Yang N, Liu Q, et al. Hydrochlorothiazide-induced glucose metabolism disorder is mediated by the gut microbiota via LPS-TLR4-related macrophage polarization. iScience. 2023;26(7):107130. doi:10.1016/j.isci.2023.107130
Zhou Q, Sun WW, Chen JC, Zhang HL, Liu J, Lin Y, et al. Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ. Nat Commun. 2022;13(1):4291. doi:10.1038/s41467-022-32000-0
Jain AB, Lai V. Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies. Diabetes Ther. 2024;15(9):2001–25. doi:10.1007/s13300-024-01628-0
Rokamp KZ, Staalsø JM, Zaar M, Rasmussen P, Petersen LG, Nielsen RV, et al. The Gly16 Allele of the G16R Single Nucleotide Polymorphism in the β2-Adrenergic Receptor Gene Augments the Glycemic Response to Adrenaline in Humans. Front Physiol. 2017;8:661. doi:10.3389/fphys.2017.00661
Tremmel R, Schreeck F, Jaeger S, Schricker S, Schaeffeler E, Igel S, et al. Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up. Clin Pharma and Therapeutics. 2026;119(1):241–54. doi:10.1002/cpt.70083
Swen JJ, Van Der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet. 2023;401(10374):347–56. doi:10.1016/S0140-6736(22)01841-4
Chen C, Lun Y, Yu J, Zhao X, Su S, Zhao M, et al. Effects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder. Front Pharmacol. 2024;15:1501381. doi:10.3389/fphar.2024.1501381
Xiao ZL, Yang M, Chen XB, Xie XM, Chen MF. Personalized antihypertensive treatment guided by pharmacogenomics in China. Cardiovasc Diagn Ther. 2022;12(5):635–45. doi:10.21037/cdt-22-154
Chan SW, Chu TTW, Ho CS, Kong APS, Tomlinson B, Zeng W. Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients. Front Med. 2021;8:683498. doi:10.3389/fmed.2021.683498
Liu Z, Cheng Z, Ye S, Zhou L, Zhou Z. Catalytic Ability Improvement of Phenylalanine Hydroxylase from Chromobacterium violaceum by N-Terminal Truncation and Proline Introduction. Journal of Microbiology and Biotechnology. 2019;29(9):1375–82.
Jan A, Alanzi A, Mothana R, Kaimori JY, Ali S, Muhammad T, et al. Pharmacogenomic Study of Selected Genes Affecting Amlodipine Blood Pressure Response in Patients with Hypertension. PGPM. 2024;Volume 17:473–86. doi:10.2147/PGPM.S481068
Wang A, Mbikyo MB, Zhang J, Cui N, Li Z, et al. Treatment for Resistant Hypertension Under the Guidance of Pharmacogenomics: A Randomised Controlled Open-Label Trial. J Coll Physicians Surg Pak. 2024;34(04):383–9. doi:10.29271/jcpsp.2024.04.383
Weinshilboum RM, Wang L. Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clinic Proceedings. 2017;92(11):1711–22. doi:10.1016/j.mayocp.2017.09.001
Briguglio W, Moghaddam P, Yousef WA, Traore I, Mamun M. Machine Learning in Precision Medicine to Preserve Privacy via Encryption. Pattern Recognition Letters. 2021;151:148–54. doi:10.1016/j.patrec.2021.07.004
Sharma S, Mariño-Ramírez L, Jordan IK. Race, Ethnicity, and Pharmacogenomic Variation in the United States and the United Kingdom. Pharmaceutics. 2023;15(7):1923. doi:10.3390/pharmaceutics15071923
Panconesi D, Murtough S, Cotic M, Khani NS, Varney L, Richards-Brown M, et al. Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals’ perceptions, knowledge, and educational needs. Pharmacogenomics J. 2026;26(1):2. doi:10.1038/s41397-025-00394-x
Ayati N, Afzali M, Hasanzad M, Kebriaeezadeh A, Rajabzadeh A, Nikfar S. Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country. IJPR. 2021;20(4). doi:10.22037/ijpr.2021.114899.15091
Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, et al. Enabling Technologies for Personalized and Precision Medicine. Trends in Biotechnology. 2020;38(5):497–518. doi:10.1016/j.tibtech.2019.12.021
Kamelia T, Putri NAR. Perkembangan PRECISION Medicine Di Indonesia. Indonesia Journal Chest. 2023;10(1):1–12.
DOI: https://doi.org/10.24198/ijpst.v13i2.60681
Refbacks
- Saat ini tidak ada refbacks.
| Switch to English Back to Top |
| View My Stats Penerbit Universitas Padjadjaran
Jurnal ini terindeks di : Creative Commons Attribution :
Based on a work at http://jurnal.unpad.ac.id/ijpst/ |
